Glipride MF 2 Tablet is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving peripheral glucose uptake, and enhancing insulin sensitivity. This synergistic combination addresses multiple pathophysiological defects in type 2 diabetes, making it effective in achieving and maintaining target blood glucose levels. Glipride MF 2 is prescribed as an adjunct to diet and exercise to improve glycemic control in patients inadequately controlled on monotherapy or lifestyle modifications alone. It is essential to monitor blood glucose levels regularly to adjust dosage appropriately and minimize the risk of hypoglycemia, particularly due to Glimepiride’s insulinotropic effect. Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, primarily attributed to Metformin. Rarely, hypoglycemia and lactic acidosis may occur, necessitating prompt medical attention. This medication should be used cautiously in patients with renal or hepatic impairment and contraindicated in conditions predisposing to hypoxia or metabolic acidosis. Glipride MF 2 Tablet offers a balanced therapeutic approach for effective glycemic management in type 2 diabetes mellitus.